This is the first report on 15d-PGJ2-induced SOCS3 expression, which evidences a novel therapeutic option for the treatment of thyroid cancer and other cancers that are dependent on IL-6 signaling. This evidence concerns the gene SOCS3 and thyroid gland carcinoma.